Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer
Nandini Pal Basak,
Kowshik Jaganathan,
Biswajit Das,
Oliyarasi Muthusamy,
Rajashekar M,
Ritu Malhotra,
Amit Samal,
Moumita Nath,
Ganesh Ms,
Amritha Prabha Shankar,
Prakash Bv,
Vijay Pillai,
Manjula Bv,
Jayaprakash C,
Vasanth K,
Gowri Shankar K,
Sindhu Govindan,
Syamkumar V,
Juby,
Koushika R,
Chandan Bhowal,
Upendra Kumar,
Govindaraj K,
Mohit Malhotra and
Satish Sankaran ()
Additional contact information
Nandini Pal Basak: Farcast Biosciences India Pvt. Ltd
Kowshik Jaganathan: Farcast Biosciences India Pvt. Ltd
Biswajit Das: Farcast Biosciences India Pvt. Ltd
Oliyarasi Muthusamy: Farcast Biosciences India Pvt. Ltd
Rajashekar M: Farcast Biosciences India Pvt. Ltd
Ritu Malhotra: Farcast Biosciences India Pvt. Ltd
Amit Samal: Farcast Biosciences India Pvt. Ltd
Moumita Nath: Farcast Biosciences India Pvt. Ltd
Ganesh Ms: Vydehi Institute of Medical Sciences & Research Centre
Amritha Prabha Shankar: Vydehi Institute of Medical Sciences & Research Centre
Prakash Bv: Sri Lakshmi Multi-Speciality Hospital
Vijay Pillai: Mazumdar Shaw Medical Center, Narayana Health
Manjula Bv: Bangalore Baptist Hospital
Jayaprakash C: DBR & SK Super Speciality Hospital
Vasanth K: Farcast Biosciences India Pvt. Ltd
Gowri Shankar K: Farcast Biosciences India Pvt. Ltd
Sindhu Govindan: Farcast Biosciences India Pvt. Ltd
Syamkumar V: Farcast Biosciences India Pvt. Ltd
Juby: Farcast Biosciences India Pvt. Ltd
Koushika R: Farcast Biosciences India Pvt. Ltd
Chandan Bhowal: Farcast Biosciences India Pvt. Ltd
Upendra Kumar: Farcast Biosciences India Pvt. Ltd
Govindaraj K: Farcast Biosciences India Pvt. Ltd
Mohit Malhotra: Farcast Biosciences India Pvt. Ltd
Satish Sankaran: Farcast Biosciences India Pvt. Ltd
Nature Communications, 2024, vol. 15, issue 1, 1-15
Abstract:
Abstract Dynamic interactions within the tumor micro-environment drive patient response to immune checkpoint inhibitors. Existing preclinical models lack true representation of this complexity. Using a Head and Neck cancer patient derived TruTumor histoculture platform, the response spectrum of 70 patients to anti-PD1 treatment is investigated in this study. With a subset of 55 patient samples, multiple assays to characterize T-cell reinvigoration and tumor cytotoxicity are performed. Based on levels of these two response parameters, patients are stratified into five sub-cohorts, with the best responder and non-responder sub-cohorts falling at extreme ends of the spectrum. The responder sub-cohort exhibits high T-cell reinvigoration, high tumor cytotoxicity with T-cells homing into the tumor upon treatment whereas immune suppression and tumor progression pathways are pre-dominant in the non-responders. Some moderate responders benefit from combination of anti-CTLA4 with anti-PD1, which is evident from better cytotoxic T-cell: T-regulatory cell ratio and enhancement of tumor cytotoxicity. Baseline and on-treatment gene expression signatures from this study stratify responders and non-responders in unrelated clinical datasets.
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:
Downloads: (external link)
https://www.nature.com/articles/s41467-024-45723-z Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45723-z
Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/
DOI: 10.1038/s41467-024-45723-z
Access Statistics for this article
Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie
More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().